Associated Papers
Advances in Precision Oncology: From Molecular Profiling to Regulatory-Approved Targeted Therapies.
Brlek P et al.
Cancers, 2025
BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?
Haguet H et al.
Th Open : Companion Journal to Thrombosis and Haemostasis, 2018
31249931 (PubMed )
Supplement: 10-1055-s-0038-1624566-s170017.pdf
Can structural features of kinase receptors provide clues on selectivity and inhibition? A molecular modeling study.
Ravichandran S et al.
Journal of Molecular Graphics & Modelling, 2015
In silico identification of novel kinase inhibitors targeting wild-type and T315I mutant ABL1 from FDA-approved drugs.
Xu HL et al.
Molecular Biosystems, 2014
BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein.
Buffa P et al.
Faseb Journal : Official Publication of the Federation of American Societies for Experimental Biology, 2014
Second-Generation Tyrosine Kinase Inhibitors (Tki) as Salvage Therapy for Resistant or Intolerant Patients to Prior TKIs.
Breccia M et al.
Mediterranean Journal of Hematology and Infectious Diseases, 2014
Molecular monitoring and mutations in chronic myeloid leukemia: how to get the most out of your tyrosine kinase inhibitor.
Baccarani M et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting, 2014
Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia.
Price KE et al.
Oncotargets and Therapy, 2013
Select a paper to view details